![]() She highlighted a €20m project known as Zapi launched in 2015 following the Ebola pandemic and which focuses on biopreparedness. In response to the report, a spokeswoman for the IMI said infectious diseases and vaccines had been a priority from the outset. “Interaction with the Coalition for Epidemic Preparedness Innovations (CEPI) continues but no immediate co-investment is expected.” “While the scope of a regulatory topic as proposed by the commission was not supported by EFPIA industries, the theme of regulatory modernisation is considered very important by industries, and will be further discussed,” the minutes record. The IMI also decided against funding projects with the Coalition for Epidemic Preparedness Innovations, a foundation seeking to tackle so-called blueprint priority diseases such as Mers and Sars, both of them coronaviruses. ![]() Minutes of a meeting of the IMI’s governing board in 2018 reveal that the proposal was not accepted. The European commission’s “biopreparedness” funding proposal in 2017 would have involved refining computer simulations, known as in silico modelling, and improved analysis of animal testing models to give regulators greater confidence in approving vaccines. The report’s authors cite a comment posted on the EFPIA’s website, since removed, selling the advantages of the initiative to big pharma as offering “tremendous cost savings, as the IMI projects replicate work that individual companies would have had to do anyway”. The CEO report says that rather than “compensating for market failures” by speeding up the development of innovative medicines, as per its remit, the IMI has been “more about business-as-usual market priorities”. One of the most promising, being developed at Oxford University, is said to have only a 50% chance of being approved for use. There are eight potential vaccines for coronavirus in clinical trials, but there is no guarantee of success. Around half were focused on treating cancer, compared with 65 on infectious diseases. The world’s 20 largest pharmaceutical companies undertook around 400 new research projects in the past year, according to Bloomberg Intelligence.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |